Dr. Isaacs Discusses the Future of Treatment for HER2+ Breast Cancer

Video

In Partnership With:

Claudine Isaacs, MD, professor, medical director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses the future of treatment for patients with HER2-positive breast cancer.

Claudine Isaacs, MD, professor, medical director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses the future of treatment for patients with HER2-positive breast cancer.

There are a number of new drugs on the horizon for the treatment of patients with HER2-positive breast cancer. The landscape has undergone a dramatic change in the past few years with the data with pertuzumab (Perjeta) in first-line, the CLEOPATRA study, and the data on ado-trastuzumab emtansine (T-DM1; Kadcyla) in the second-line setting, says Isaacs.

Patients were doing well for so long, that clinical trial accruement was somewhat of a challenge, Isaacs says. However, there are a lot of exciting agents and combinations on the horizon, such as tucatinib (ONT-380), which may have the ability to penetrate the blood-brain barrier in patients with HER2-positive breast cancer. Additionally, there is interest in looking at immunotherapy with HER2-targeted therapies, as well as CDK4/6 inhibitors in combination with HER2-targeted therapies.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,